ACADIA Pharmaceuticals Net Income 2006-2021 | ACAD
For a detailed definition, formula and example for Net Income, check out our new background page here.
ACADIA Pharmaceuticals net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ACADIA Pharmaceuticals Annual Net Income
(Millions of US $) |
| 2020 |
$-282 |
| 2019 |
$-235 |
| 2018 |
$-245 |
| 2017 |
$-289 |
| 2016 |
$-271 |
| 2015 |
$-164 |
| 2014 |
$-92 |
| 2013 |
$-38 |
| 2012 |
$-21 |
| 2011 |
$-23 |
| 2010 |
$15 |
| 2009 |
$-45 |
| 2008 |
$-64 |
| 2007 |
$-56 |
| 2006 |
$-45 |
| 2005 |
$-34 |
ACADIA Pharmaceuticals Quarterly Net Income
(Millions of US $) |
| 2021-09-30 |
$-14 |
| 2021-06-30 |
$-44 |
| 2021-03-31 |
$-66 |
| 2020-12-31 |
$-67 |
| 2020-09-30 |
$-85 |
| 2020-06-30 |
$-42 |
| 2020-03-31 |
$-88 |
| 2019-12-31 |
$-53 |
| 2019-09-30 |
$-42 |
| 2019-06-30 |
$-55 |
| 2019-03-31 |
$-85 |
| 2018-12-31 |
$-65 |
| 2018-09-30 |
$-62 |
| 2018-06-30 |
$-63 |
| 2018-03-31 |
$-54 |
| 2017-12-31 |
$-69 |
| 2017-09-30 |
$-65 |
| 2017-06-30 |
$-67 |
| 2017-03-31 |
$-88 |
| 2016-12-31 |
$-79 |
| 2016-09-30 |
$-72 |
| 2016-06-30 |
$-71 |
| 2016-03-31 |
$-50 |
| 2015-12-31 |
$-46 |
| 2015-09-30 |
$-39 |
| 2015-06-30 |
$-39 |
| 2015-03-31 |
$-40 |
| 2014-12-31 |
$-28 |
| 2014-09-30 |
$-25 |
| 2014-06-30 |
$-21 |
| 2014-03-31 |
$-18 |
| 2013-12-31 |
$-12 |
| 2013-09-30 |
$-11 |
| 2013-06-30 |
$-9 |
| 2013-03-31 |
$-6 |
| 2012-12-31 |
$-7 |
| 2012-09-30 |
$-2 |
| 2012-06-30 |
$-5 |
| 2012-03-31 |
$-6 |
| 2011-12-31 |
$-5 |
| 2011-09-30 |
$-5 |
| 2011-06-30 |
$-7 |
| 2011-03-31 |
$-6 |
| 2010-12-31 |
$29 |
| 2010-09-30 |
$-4 |
| 2010-06-30 |
$-4 |
| 2010-03-31 |
$-5 |
| 2009-12-31 |
$-9 |
| 2009-09-30 |
$-9 |
| 2009-06-30 |
$-13 |
| 2009-03-31 |
$-15 |
| 2008-12-31 |
$-14 |
| 2008-09-30 |
$-16 |
| 2008-06-30 |
$-18 |
| 2008-03-31 |
$-16 |
| 2007-12-31 |
$-17 |
| 2007-09-30 |
$-16 |
| 2007-06-30 |
$-11 |
| 2007-03-31 |
$-13 |
| 2006-12-31 |
$-12 |
| 2006-09-30 |
$-11 |
| 2006-06-30 |
$-12 |
| 2006-03-31 |
$-9 |
| 2005-12-31 |
$-10 |
| 2005-09-30 |
$-12 |
| 2005-06-30 |
$-6 |
| 2005-03-31 |
$-6 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.705B |
$0.442B |
|
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
|
